{"schema_version":"secwatch.filing_event.v1","accession":"0001005286-23-000108","form_type":"8-K","ticker":"LFCR","cik":"0001005286","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-08-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.836186+00:00","generated_at":"2026-06-11T00:53:20.676581+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lifecore Biomedical Q4 revenue up 12% to $31.5M; net loss widens to $33.8M on debt refinancing","bullets":["Q4 consolidated revenue $31.5M (+12.2% YoY); gross profit $8.4M (-33.9% YoY); net loss from continuing ops $33.8M vs $1.0M loss prior year.","Full year FY2023 revenue $103.3M (-7.2% YoY); net loss from continuing ops $69.0M; adjusted EBITDA $5.8M vs $22.9M prior year.","Q4 net loss includes $23.8M loss on debt refinancing and $6.8M restructuring/legal charges; adjusted EBITDA fell to $3.7M from $9.1M.","CEO notes final divestitures of Curation Foods, expanded supply agreement with Alcon, and new customer projects added in Q4.","Capacity expansions: multi-use fillers to double filling capacity to ~45M units; HA fermentation moving to 24/7 to boost capacity up to 50% by June 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001005286-23-000108","json":"https://secwatch.observer/filing/0001005286-23-000108.json","markdown":"https://secwatch.observer/filing/0001005286-23-000108.md","text":"https://secwatch.observer/filing/0001005286-23-000108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000108/0001005286-23-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000108/lndc-20230831.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:53:20.676581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0d196ca04fd5737160ea9956e8c94365d2df9c3","claim":"LIFECORE BIOMEDICAL, INC. DE reported the fourth quarter and full year of fiscal 2023 ended May 28, 2023 results: revenue $31.5 million, net income Net loss from continuing operations of $33.8 million.","evidence_excerpt":"fiscal 2024 second quarter and to a greater degree in the second half of the fiscal year.\" LIFECORE FISCAL FOURTH QUARTER 2023 FINANCIAL HIGHLIGHTS: • Consolidated revenues of $31.5 million, an increase of 12.2% year-over-year. • Consolidated gross profit of $8.4 million, a decrease of $4.3 million, or 33.9% year-over-year • Consolidated net loss from continuing","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000108/0001005286-23-000108-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year of fiscal 2023 ended May 28, 2023"},{"label":"Revenue","value":"$31.5 million"},{"label":"Net income","value":"Net loss from continuing operations of $33.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}